leadf
logo-loader
viewElixinol Wellness Ltd
(
ASX:EXLOTCQB:ELLXFFRA:E8M
)

Elixinol Global's products pass key administrative check by Food Standards Agency and can remain for sale in UK market

The FSA novel foods approval is expected to open up new opportunities for customer contracts.

Elixinol Global Ltd -
The FSA had set a deadline for CBD businesses to submit valid novel food applications to permit the continued sale of CBD products in the UK.

Elixinol Global Ltd (ASX:EXL) (OTCQB:ELLXF) has been notified by the European Industrial Hemp Association (EIHA) that both full-spectrum and natural isolate products of EIHA’s Novel Food Consortium partners can remain for sale on the UK market.

Both applications have passed the key administrative check by the UK Food Standards Agency (FSA). 

Official validation will be granted upon results of toxicological studies on both CBD and THC1, expected in the coming months.

In the meantime, it will be business as usual for Elixinol UK sales.

New opportunities for customer contracts

Elixinol executive director and global chief executive officer Oliver Horn said: “This is excellent news from the UK.

“The FSA’s response means we can continue to operate on a business as usual basis for now, while the toxicological work is being undertaken.

“It removes a short-term risk and will open up new opportunities for customer contracts.

“We will keep the market appraised as this matter develops further over the coming months.”

Applications compliant

The FSA had set a deadline of March 31, 2021, for CBD businesses such as Elixinol to submit valid novel food applications to permit the continued sale of CBD products in the UK.

As a partner of EIHA’s consortium, Elixinol’s products are now supported by a valid novel food application.

The FSA had confirmed to EIHA that the applications were considered to be compliant with the administrative requirements.

The official validation will be granted only upon results of the undergoing toxicological studies on both CBD and THC1, expected in the coming months.

Quick facts: Elixinol Wellness Ltd

Follow
ASX:EXL

Price: 0.11 AUD

Market Cap: $34.7 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Elixinol Wellness feeling increasingly positive after 'significantly...

  Elixinol Wellness Ltd (ASX:EXL, OTCQB:ELLXF, FRA:E8M)'s Oliver Horn speaks to Proactive following the news of a 53% improvement in EBITDA on the previous corresponding period - its best earnings result since the first half of 2019. Horn says they've continued to deliver on its strategy to...

on 08/17/2021

2 min read